DEFINITIONS

In this prospectus, unless the context otherwise requires, the following terms shall

have the meanings set out below. Certain other terms are explained in “Glossary”.

“affiliate(s)”

“Application Form(s)”

“Articles” or “Articles of

Association”

“ASCO”

with respect to any specified person, any other person,
directly or indirectly, controlling or controlled by or
under direct or
indirect common control with such
specified person

WHITE application form(s), YELLOW application
form(s) and GREEN application form(s), or where the
context so requires, any of them, relating to the Hong
Kong Public Offering

the articles of association of our Company conditionally
adopted by our Shareholders on June 6, 2018 to take
effect on the Listing Date, as amended or supplemented
from time to time, a summary of which is set out in
Appendix IV to this prospectus

American Society of Clinical Oncology, a professional
organization whose members include physicians of all
oncology sub-specialties; it is one of the major sponsors
for Gastrointestinal Cancers Symposium (ASCO-GI), a
specialized oncology event

“associate(s)”

has the meaning ascribed thereto under the Listing Rules

“Beijing Junkejingde”

“Beijing Tianshi”

“Beijing Union Biopharm”

Beijing Junkejingde Biotechnology Co., Ltd.* (北京軍科
鏡德生物科技有限責任公司), a limited liability company
established in the PRC on April 3, 2015 and a direct
non-wholly-owned subsidiary of our Company

Beijing Tianshi Pharmaceutical Technology Co., Ltd.*
(北京天實醫藥科技有限公司),
liability
company established in the PRC on April 22, 2016, which
is owned as to 50% by our Company

limited

a

Beijing Union Biopharm Junshi Biosciences Co., Ltd.*
(北京眾合君實生物醫藥科技有限公司),
limited
liability company established in the PRC on June 12,
2016 and an indirect wholly-owned subsidiary of our
Company

a

– 19 –

